GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » LT-Debt-to-Total-Asset

Entheon Biomedical (Entheon Biomedical) LT-Debt-to-Total-Asset : 0.00 (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Entheon Biomedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Entheon Biomedical's long-term debt to total assests ratio for the quarter that ended in Feb. 2024 was 0.00.

Entheon Biomedical's long-term debt to total assets ratio stayed the same from Feb. 2023 (0.00) to Feb. 2024 (0.00).

Entheon Biomedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Entheon Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical LT-Debt-to-Total-Asset Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - - - - -

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entheon Biomedical LT-Debt-to-Total-Asset Calculation

Entheon Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2023 is calculated as

LT Debt to Total Assets (A: Nov. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Nov. 2023 )/Total Assets (A: Nov. 2023 )
=0/0.293
=0.00

Entheon Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

LT Debt to Total Assets (Q: Feb. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2024 )/Total Assets (Q: Feb. 2024 )
=0/0.216
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical  (OTCPK:ENTBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Entheon Biomedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (Entheon Biomedical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
XCNQ:MYND XCNQ:ABRT XCNQ:WESA.X TSXV:BTI XCNQ:HAVN TSXV:IBO XCNQ:GTTX TSXV:APC.H XCNQ:MOOD XCNQ:NSHS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1XU1:Germany ENBI:Canada
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Website
https://www.entheonbiomedical.com
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.